Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha

References

• Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 inhibitors and the diabetic kidney. Diabetes Care. 2016;39(Suppl 2):S165–S171. doi:10.2337/dcS15-3006
   PubMed Web of Science ®Google Scholar
• Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2016;5(1):49–56.
   PubMedGoogle Scholar
• Panchapakesan U, Pegg K, Gross S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells–renoprotection in diabetic nephropathy? PLoS One. 2013;8(2):e54442. doi:10.1371/journal.pone.0054442
   PubMed Web of Science ®Google Scholar
• Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281. doi:10.1016/j.diabres.2018.02.023
   PubMed Web of Science ®Google Scholar
• Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50. doi:10.1016/j.diabres.2017.03.024
   PubMed Web of Science ®Google Scholar
• Toth-Manikowski S, Atta MG. Diabetic kidney disease: pathophysiology and therapeutic targets. J Diabetes Res. 2015;2015:697010. doi:10.1155/2015/697010
   PubMed Web of Science ®Google Scholar
• Lim A. Diabetic nephropathy - complications and treatment. Int J Nephrol Renovasc Dis. 2014;7:361–381. doi:10.2147/IJNRD.S40172
   PubMedGoogle Scholar
• American Diabetes A. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37(Suppl 1):S14–S80.
   PubMed Web of Science ®Google Scholar
• Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215–225. doi:10.1007/s00125-016-4157-3
   PubMed Web of Science ®Google Scholar
• Tonneijck L, Muskiet MH, Smits MM, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017;28(4):1023–1039. doi:10.1681/ASN.2016060666
   PubMed Web of Science ®Google Scholar
• Hills CE, Squires PE. TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol. 2010;31(1):68–74. doi:10.1159/000256659
   PubMed Web of Science ®Google Scholar
• Layton AT, Vallon V, Edwards A. Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition. Am J Physiol Renal Physiol. 2015;308(12):F1343–F1357. doi:10.1152/ajprenal.00007.2015
   PubMed Web of Science ®Google Scholar
• Ito M, Tanaka T. The anticipated renoprotective effects of sodium-glucose cotransporter 2 inhibitors. Internal Medx. 2018;57(15):2105–2114. doi:10.2169/internalmedicine.9842-17
   PubMedGoogle Scholar
• Ghezzi C, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. 2018;61(10):2087–2097. doi:10.1007/s00125-018-4656-5
   PubMed Web of Science ®Google Scholar
• Jiao Y, Jiang H, Lu H, et al. Deficiency of hypoxia inducible factor-1alpha promoted progression of diabetic nephropathy with hypertension. Exp Ther Med. 2018;16(4):3658–3662. doi:10.3892/etm.2018.6621
   PubMedGoogle Scholar
• Katavetin P, Miyata T, Inagi R, et al. High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathway. J Am Soc Nephrol. 2006;17(5):1405–1413. doi:10.1681/ASN.2005090918
   PubMedGoogle Scholar
• Semenza GL. Oxygen homeostasis. Wiley Interdiscip Rev Syst Biol Med. 2010;2(3):336–361. doi:10.1002/wsbm.69
   PubMed Web of Science ®Google Scholar
• Bento CF, Pereira P. Regulation of hypoxia-inducible factor 1 and the loss of the cellular response to hypoxia in diabetes. Diabetologia. 2011;54(8):1946–1956. doi:10.1007/s00125-011-2191-8
   PubMed Web of Science ®Google Scholar
• Isoe T, Makino Y, Mizumoto K, et al. High glucose activates HIF-1-mediated signal transduction in glomerular mesangial cells through a carbohydrate response element binding protein. Kidney Int. 2010;78(1):48–59. doi:10.1038/ki.2010.99
   PubMed Web of Science ®Google Scholar
• Nayak BK, Shanmugasundaram K, Friedrichs WE, et al. HIF-1 mediates renal fibrosis in OVE26 type 1 diabetic mice. Diabetes. 2016;65(5):1387–1397. doi:10.2337/db15-0519
   PubMed Web of Science ®Google Scholar
• Kabei K, Tateishi Y, Nozaki M, et al. Role of hypoxia-inducible factor-1 in the development of renal fibrosis in mouse obstructed kidney: special references to HIF-1 dependent gene expression of profibrogenic molecules. J Pharmacol Sci. 2018;136(1):31–38. doi:10.1016/j.jphs.2017.12.004
   PubMed Web of Science ®Google Scholar
• Nordquist L, Friederich-Persson M, Fasching A, et al. Activation of hypoxia-inducible factors prevents diabetic nephropathy. J Am Soc Nephrol. 2015;26(2):328–338. doi:10.1681/ASN.2013090990
   PubMed Web of Science ®Google Scholar
• Chang YK, Choi H, Jeong JY, et al. Correction: dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One. 2016;11(7):e0160478. doi:10.1371/journal.pone.0160478
   Google Scholar
• Zhang YJ, Han SL, Sun XF, et al. Efficacy and safety of empagliflozin for type 2 diabetes mellitus: meta-analysis of randomized controlled trials. Medicine. 2018;97(43):e12843. doi:10.1097/MD.0000000000012843
   PubMed Web of Science ®Google Scholar
• Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther. 2014;5(2):355–366. doi:10.1007/s13300-014-0089-4
   PubMed Web of Science ®Google Scholar
• Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255–270. doi:10.1146/annurev-med-051013-110046
   PubMed Web of Science ®Google Scholar
• Bessho R, Takiyama Y, Takiyama T, et al. Hypoxia-inducible factor-1alpha is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Sci Rep. 2019;9(1):14754. doi:10.1038/s41598-019-51343-1
   PubMedGoogle Scholar
• Chang Y-K, Choi H, Jeong JY, et al. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One. 2016;11(7):e0158810. doi:10.1371/journal.pone.0158810
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi:10.1056/NEJMoa1811744
   PubMed Web of Science ®Google Scholar
• Maki T, Maeno S, Maeda Y, et al. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: a possible role of SGLT2 in mesangial cells. Sci Rep. 2019;9(1):4703. doi:10.1038/s41598-019-41253-7
   PubMedGoogle Scholar
• Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic akita mice. Am J Physiol Renal Physiol. 2014;306(2):F194–F204. doi:10.1152/ajprenal.00520.2013
   PubMed Web of Science ®Google Scholar
• Li H, Satriano J, Thomas JL, et al. Interactions between HIF-1alpha and AMPK in the regulation of cellular hypoxia adaptation in chronic kidney disease. Am J Physiol Renal Physiol. 2015;309(5):F414–F428. doi:10.1152/ajprenal.00463.2014
   Google Scholar
• Schonenberger MJ, Kovacs WJ. Hypoxia signaling pathways: modulators of oxygen-related organelles. Front Cell Dev Biol. 2015;3:42. doi:10.3389/fcell.2015.00042
   PubMed Web of Science ®Google Scholar
• Song YR, You SJ, Lee YM, et al. Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney. Nephrol Dial Transplant. 2010;25(1):77–85. doi:10.1093/ndt/gfp454
   Google Scholar
• Jin J, Jin L, Luo K, Lim SW, Chung BH, Yang CW. Effect of empagliflozin on tacrolimus-induced pancreas islet dysfunction and renal injury. Am J Transplant. 2017;17(10):2601–2616. doi:10.1111/ajt.14316
   PubMed Web of Science ®Google Scholar
• Cassis P, Locatelli M, Cerullo D, et al. SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight. 2018;3(15). doi:10.1172/jci.insight.98720
   Google Scholar
• Zapata-Morales JR, Galicia-Cruz OG, Franco M, Martinez YMF. Hypoxia-inducible factor-1alpha (HIF-1alpha) protein diminishes sodium glucose transport 1 (SGLT1) and SGLT2 protein expression in renal epithelial tubular cells (LLC-PK1) under hypoxia. J Biol Chem. 2014;289(1):346–357. doi:10.1074/jbc.M113.526814
   Google Scholar
• Layton AT, Vallon V, Edwards A. Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron. Am J Physiol Renal Physiol. 2016;310(11):F1269–1283. doi:10.1152/ajprenal.00543.2015
   Google Scholar
• Ono H, Abe H, Sakurai A, et al. Novel interplay between Smad1 and Smad3 phosphorylation via AGE regulates the progression of diabetic nephropathy. Sci Rep. 2018;8(1):10548. doi:10.1038/s41598-018-28439-1
   Google Scholar
• Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15. doi:10.1186/s12933-019-0816-2
   PubMedGoogle Scholar
• Huang F, Zhao Y, Wang Q, et al. Dapagliflozin attenuates renal tubulointerstitial fibrosis associated with type 1 diabetes by regulating STAT1/TGFbeta1 signaling. Front Endocrinol (Lausanne). 2019;10:441. doi:10.3389/fendo.2019.00441
   PubMed Web of Science ®Google Scholar
• Hou S, Zheng F, Li Y, Gao L, Zhang J. The protective effect of glycyrrhizic acid on renal tubular epithelial cell injury induced by high glucose. Int J Mol Sci. 2014;15(9):15026–15043. doi:10.3390/ijms150915026
   PubMed Web of Science ®Google Scholar
• Inoue MK, Matsunaga Y, Nakatsu Y, et al. Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice. Diabetol Metab Syndr. 2019;11:57. doi:10.1186/s13098-019-0454-6
   PubMed Web of Science ®Google Scholar
• Kaji K, Nishimura N, Seki K, et al. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer. 2018;142(8):1712–1722. doi:10.1002/ijc.31193
   PubMed Web of Science ®Google Scholar
• Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019;139(11):1384–1395. doi:10.1161/CIRCULATIONAHA.118.037778
   PubMed Web of Science ®Google Scholar